Verition Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.07M | Buy |
3,312
+1,834
| +124% | +$1.25M | 0.01% | 1086 |
|
|
2026
Q1 | $1.14M | Sell |
1,478
-8,013
| -84% | -$6.13M | 0.01% | 1254 |
|
|
2025
Q4 | $7.33M | Sell |
9,491
-6,933
| -42% | -$4.71M | 0.03% | 622 |
|
|
2025
Q3 | $9.23M | Sell |
16,424
-5,378
| -25% | -$3.04M | 0.04% | 576 |
|
|
2025
Q2 | $11.4M | Buy |
21,802
+1,678
| +8% | +$937K | 0.05% | 450 |
|
|
2025
Q1 | $12.8M | Sell |
20,124
-6,187
| -24% | -$4.26M | 0.06% | 368 |
|
|
2024
Q4 | $18.7M | Buy |
26,311
+25,257
| +2,396% | +$21.2M | 0.07% | 259 |
|
|
2024
Q3 | $1.11M | Sell |
1,054
-7,499
| -88% | -$8.35M | 0.01% | 1813 |
|
|
2024
Q2 | $8.99M | Sell |
8,553
-4,679
| -35% | -$4.54M | 0.05% | 400 |
|
|
2024
Q1 | $12.7M | Buy |
13,232
+8,451
| +177% | +$8.04M | 0.09% | 238 |
|
|
2023
Q4 | $4.2M | Buy |
+4,781
| New | +$3.94M | 0.03% | 505 |
|
|
2023
Q3 | – | Sell |
-765
| Closed | -$601K | – | 2626 |
|
|
2023
Q2 | $550K | Buy |
765
+34
| +5% | +$26.2K | 0.01% | 1189 |
|
|
2023
Q1 | $601K | Sell |
731
-12,941
| -95% | -$9.76M | 0.01% | 1138 |
|
|
2022
Q4 | $9.86M | Buy |
13,672
+12,986
| +1,893% | +$9.58M | 0.15% | 156 |
|
|
2022
Q3 | $473K | Sell |
686
-1,194
| -64% | -$751K | 0.01% | 1931 |
|
|
2022
Q2 | $1.11M | Buy |
1,880
+1,322
| +237% | +$859K | 0.02% | 963 |
|
|
2022
Q1 | $390K | Sell |
558
-465
| -45% | -$294K | ﹤0.01% | 2045 |
|
|
2021
Q4 | $646K | Sell |
1,023
-459
| -31% | -$282K | ﹤0.01% | 1561 |
|
|
2021
Q3 | $897K | Sell |
1,482
-779
| -34% | -$484K | 0.01% | 978 |
|
|
2021
Q2 | $1.26M | Buy |
+2,261
| New | +$1.15M | 0.01% | 704 |
|
|
2020
Q4 | – | Sell |
-755
| Closed | -$423K | – | 1348 |
|
|
2020
Q3 | $423K | Sell |
755
-144
| -16% | -$87.3K | 0.01% | 640 |
|
|
2020
Q2 | $561K | Buy |
+899
| New | +$510K | 0.02% | 569 |
|
|
2020
Q1 | – | Sell |
-3,528
| Closed | -$1.32M | – | 978 |
|
|
2019
Q4 | $1.32M | Sell |
3,528
-9,403
| -73% | -$3.16M | 0.02% | 368 |
|
|
2019
Q3 | $3.59M | Buy |
12,931
+2,437
| +23% | +$721K | 0.1% | 141 |
|
|
2019
Q2 | $3.29M | Buy |
10,494
+9,519
| +976% | +$3.17M | 0.09% | 155 |
|
|
2019
Q1 | $400K | Buy |
+975
| New | +$401K | 0.02% | 737 |
|
|
2018
Q4 | – | Sell |
-3,682
| Closed | -$1.49M | – | 1171 |
|
|
2018
Q3 | $1.49M | Buy |
+3,682
| New | +$1.4M | 0.05% | 417 |
|
|
2018
Q1 | – | Sell |
-1,835
| Closed | -$690K | – | 1285 |
|
|
2017
Q4 | $690K | Sell |
1,835
-88
| -5% | -$35.6K | 0.06% | 375 |
|
|
2017
Q3 | $860K | Buy |
1,923
+8
| +0.4% | +$3.81K | 0.07% | 348 |
|
|
2017
Q2 | $941K | Buy |
1,915
+1,126
| +143% | +$493K | 0.09% | 211 |
|
|
2017
Q1 | $306K | Sell |
789
-1,829
| -70% | -$678K | 0.03% | 839 |
|
|
2016
Q4 | $961K | Buy |
+2,618
| New | +$996K | 0.08% | 284 |
|
|
2016
Q3 | – | Sell |
-4,885
| Closed | -$1.71M | – | 1275 |
|
|
2016
Q2 | $1.71M | Buy |
4,885
+2,405
| +97% | +$926K | 0.22% | 95 |
|
|
2016
Q1 | $894K | Buy |
2,480
+1,868
| +305% | +$770K | 0.14% | 156 |
|
|
2015
Q4 | $332K | Buy |
612
+128
| +26% | +$69.4K | 0.06% | 276 |
|
|
2015
Q3 | $225K | Buy |
+484
| New | +$260K | 0.06% | 433 |
|
|
2015
Q1 | – | Sell |
-514
| Closed | -$211K | – | 482 |
|
|
2014
Q4 | $211K | Sell |
514
-331
| -39% | -$130K | 0.05% | 233 |
|
|
2014
Q3 | $305K | Sell |
845
-3,540
| -81% | -$1.19M | 0.04% | 392 |
|
|
2014
Q2 | $1.24M | Buy |
4,385
+2,173
| +98% | +$644K | 0.13% | 97 |
|
|
2014
Q1 | $664K | Buy |
2,212
+1,257
| +132% | +$387K | 0.1% | 133 |
|
|
2013
Q4 | $263K | Sell |
955
-2,109
| -69% | -$607K | 0.05% | 309 |
|
|
2013
Q3 | $959K | Buy |
3,064
+343
| +13% | +$90.2K | 0.15% | 118 |
|
|
2013
Q2 | $612K | Buy |
+2,721
| New | +$634K | 0.11% | 182 |
|
Other funds holding REGN
Verition Fund Management's REGN Position: Q2 2026 in Review
Verition Fund Management increased its Regeneron Pharmaceuticals (REGN) stake by 124% in Q2 2026, buying an estimated $1.25M and bringing the position to 3,312 shares worth $2.07M. The position accounts for 0.01% of the portfolio, ranked #1086.
Verition Fund Management first reported a position in REGN in Q2 2013 and has held it in 43 quarters since. The position peaked at $18.7M in Q4 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Verition Fund Management held 3,312 shares of Regeneron Pharmaceuticals worth $2.07M as of Q2 2026.
- Verition Fund Management bought 1,834 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.25M.
- Regeneron Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1086 holding.
- Verition Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Verition Fund Management's Regeneron Pharmaceuticals position peaked at $18.7M in Q4 2024.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.